SLU-PP-332
ERR alpha agonist
SLU-PP-332 is a small molecule agonist of the estrogen-related receptors (ERRs), particularly ERR-alpha and ERR-gamma, developed at Saint Louis University as an exercise mimetic that enhances muscle endurance and fatigue resistance without physical training. It is not technically a peptide but a synthetic small molecule that activates transcription factors controlling mitochondrial biogenesis, oxidative metabolism, and muscle fiber type composition. Published in 2023, it represents one of the newest entries in the exercise mimetic compound class and remains in very early preclinical development.
Meccanismo d'azione
ERRa agonist that mimics the transcriptional effects of exercise. Activates mitochondrial biogenesis and oxidative metabolism pathways.
Protocolli di ricerca
Solo per scopi di ricerca. Non è consiglio medico.
Research protocols limited to animal studies. Mouse models used 25-50mg/kg. No established human dosing.
Note di ricerca
Clinical Research Status
SLU-PP-332 was first published in the Journal of Pharmacology and Experimental Therapeutics in 2023 by researchers at Saint Louis University, representing extremely early-stage preclinical research with only animal data available. No clinical trials have been registered or planned for human testing, and the compound remains purely a research tool for understanding ERR biology and exercise physiology. Its emergence has generated media attention as a potential "exercise in a pill" compound, though such applications remain speculative and distant from clinical reality.
Key Published Findings
Mouse studies demonstrate that SLU-PP-332 administration increased running endurance by approximately 50% on treadmill exhaustion tests and enhanced fatigue-resistant oxidative (Type I and IIa) muscle fiber proportions without exercise training. The compound activates ERR-alpha and ERR-gamma transcription factors, which are master regulators of mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation gene programs in skeletal muscle. Treated animals showed increased muscle mitochondrial density, enhanced oxidative capacity, and gene expression profiles resembling those of trained athletes.
Safety Profile
Formal toxicology studies have not been published, and the safety profile of SLU-PP-332 in any species is largely unknown beyond the limited animal experiments reported. ERR receptors are expressed in multiple tissues including heart, kidney, and brain, raising theoretical concerns about off-target effects from systemic ERR activation. The structural novelty of the compound means there is no existing clinical safety data from related molecules to extrapolate from, unlike older exercise mimetics with more established safety profiles.
Comparison to Related Compounds
SLU-PP-332 targets a different pathway than AICAR (AMPK activation) or GW501516 (PPAR-delta activation), representing a third distinct molecular approach to exercise mimicry through the ERR transcription factor family. While GW501516 demonstrated concerning carcinogenicity in long-term animal studies, whether ERR agonism carries similar risks is unknown due to the early stage of research. Unlike both AICAR and GW501516 which have years of research history and some human data, SLU-PP-332 has only a single primary publication and minimal characterization.
Community Observations
Interest in SLU-PP-332 has been driven primarily by mainstream media coverage framing it as an "exercise pill," generating excitement in fitness and longevity communities. The compound is not commercially available from any legitimate source as of current reports, and anyone claiming to sell it likely cannot verify identity or purity. Experienced researchers in the performance enhancement space advise patience, noting that the journey from initial publication to any form of human-ready compound typically spans 10-15 years of development.
Semplifichro
~4-6 hours
Riconcimimento
DMSO or appropriate vehicle
Conservazione
Lyofilizzato
Store at -20C. Protect from light and moisture.
Riconcimato
Store at -20C in solution.
Stato legale USA
Anche noto come
Domande frequenti
Che cos'è SLU-PP-332?
SLU-PP-332 is a small molecule agonist of the estrogen-related receptors (ERRs), particularly ERR-alpha and ERR-gamma, developed at Saint Louis University as an exercise mimetic that enhances muscle endurance and fatigue resistance without physical training. It is not technically a peptide but a synthetic small molecule that activates transcription factors controlling mitochondrial biogenesis, oxidative metabolism, and muscle fiber type composition. Published in 2023, it represents one of the newest entries in the exercise mimetic compound class and remains in very early preclinical development.
Come agisce SLU-PP-332?
ERRa agonist that mimics the transcriptional effects of exercise. Activates mitochondrial biogenesis and oxidative metabolism pathways.
Qual è lo stato normativo di SLU-PP-332 negli Stati Uniti?
Research chemical (not FDA-approved)
Qual è l'emivita di SLU-PP-332?
~4-6 hours
Con quali altri nomi è noto SLU-PP-332?
ERR alpha agonist
Peptide Contacts fornisce riassunti basati su ricerche a fini informativi soltanto. Non ospitiamo, distribuiamo o endossiamo le comunicazioni dei fornitori. Tutti i certificati di analisi, certificati GMP e comunicazioni del fornitore devono essere richiesti e verificati direttamente dall'acquirente. Niente su questa piattaforma costituisce consigli legali, medici o professionali. I utenti sono responsabili unicamente della verifica delle credenziali dei fornitori e dell'assicurazione del rispetto di tutte le leggi locali, regionali e federali applicabili prima di acquistare qualsiasi chimica di ricerca. L'uso di questa piattaforma costituisce l'accettazione piena della responsabilità personale.
Leggi l'intera dichiarazione di responsabilità